A significantly greater proportion of patients treated with PD-L1 inhibitors had de novo metastatic disease (67.3% vs. 45.2% p-value < 0.001) as well as visceral metastases (80.4% vs. 66.1% p = 0.004). This evidence concerns the gene CD274 and metastatic neoplasm.